Drugs / VH4524184
VH4524184
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07636928 | Jun → Aug 2026 overdue | HIV infectious disease | ViiV Healthcare | Recruiting | No outcome recorded |
| Phase 1 | NCT07066722 | Jul → Dec 2025 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT06310551 | Mar 2024 → Jan 2028 expected | HIV infectious disease | ViiV Healthcare | Recruiting | No outcome recorded |
| Phase 1 | NCT06310616 | Mar → Aug 2024 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT05631704 | Dec 2022 → Jul 2023 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07202546 | Feb 2026 → Jul 2027 expected | HIV infectious disease | ViiV Healthcare | Recruiting | No outcome recorded |
| Phase 2 | NCT06214052 | Feb → Jun 2024 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VH4524184 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07066722 ↗ |
| Known as | [14C]VH4524184 | “Drug: [14C]VH4524184” NCT07636928 ↗ |
| Known as | GSK4524184 | “This study is designed to investigate the safety, tolerability and PK of VH4524184 (GSK4524184) and the potential of VH4524184 to inhibit or induce CYP3A activity in healthy...” NCT05631704 ↗ |
| Known as | VH-184 | “VH4524184 (VH-184) is an emerging third-generation integrase strand transfer inhibitor (INSTI) with an enhanced in vitro resistance profile compared with second-generation...” PMID 42283218 ↗ Jun 20261“VH4524184 (VH-184) is a third-generation INSTI with long-acting potential currently in development for HIV-1 treatment.” PMID 40117383 ↗ Oct 2025 |
| Action | Inhibit | “Phase 1 Evaluation of VH4524184, a Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile.” PMID 40117383 ↗ Oct 2025 |
| Route | Oral | “This double-blind, randomized, placebo-controlled, phase 1, first-time-in-human (FTIH) study evaluated oral VH-184 in adults without HIV-1 administered as single ascending...” PMID 40117383 ↗ Oct 2025 |